[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.87.121.0. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 402
Citations 0
Correction
October 10, 2012

Incorrect Data and Conflict of Interest Disclosures in: Number and Order of Whole Cell Pertussis Vaccines in Infancy and Disease Protection

JAMA. 2012;308(14):1432. doi:10.1001/2012.jama.12232

Incorrect Data and Conflict of Interest Disclosures: In the Research Letter entitled “Number and Order of Whole Cell Pertussis Vaccines in Infancy and Disease Protection” published in the August 1, 2012, issue of JAMA (2012;308[5]:454-456), incorrect data appear in 2 places. The first sentence of the Results section should be “Of 58 233 children born in 1998 identified in the QVR, 40 694 (69.9%) received at least 3 doses of any pertussis-containing vaccine during the first year from a Queensland vaccine service provider and were included in the analysis.” In the Table, the footnote “a” should be “A primary vaccination course is defined as 3 or more doses of a pertussis-containing vaccine for infants younger than 12 months of age. Analysis excludes records for infants with no vaccination history recorded before 12 months of age (n = 6806), those with vaccination history provided by outside source (not a Queensland vaccine service provider; n = 4129), those with irregularity of the vaccine dose by number or description (n = 192), and those with less than 3 vaccination doses recorded (n = 6412).” The second sentence of the Conflict of Interest Disclosures section should be “Drs Grimwood and Lambert reported receiving honoraria for serving on the GlaxoSmithKline advisory boards for pneumonia and pneumonia conjugate vaccine. Dr Lambert also reported serving as an investigator on clinical studies sponsored by GlaxoSmithKline and sanofi-pasteur (both manufacturers of pertussis-containing vaccines), and serving on GlaxoSmithKline and sanofi-pasteur advisory boards for pneumococcal and influenza vaccines, respectively.” This article has been corrected online.

×